Alberto Hernando-Calvo

All papers authored by Alberto Hernando-Calvo

This paper was not found in any repository, but could be made available legally by the author.

2024 Alberto Hernando-Calvo

, Alice Rossi, Maria Vieito, Emile Voest, Elena Garralda

Agnostic drug development revisited

Upload

Pablo Jiménez-Labaig, Antonio Rullan, Irene Braña, Alberto Hernando-Calvo

, Victor Moreno

, Bernard Doger, George Bitar

, Derfel Ap Dafydd, Alan Melcher

, Kevin J. Harrington

Intratumoral therapies in head and neck squamous cell carcinoma: A systematic review and future perspectives

Upload

This paper is made freely available by the publisher.

Alberto Hernando-Calvo

, Paul Nguyen, Philippe L. Bedard, Kelvin K. W. Chan, Ramy R. Saleh, Deirdre Weymann, Celeste Yu, Eitan Amir

, Dean A. Regier, Bishal Gyawali, Danielle Kain, Brooke Wilson, Craig C. Earle, Nicole Mittmann, Albiruni R. Abdul Razak and 8 other authors

Impact on costs and outcomes of multi-gene panel testing for advanced solid malignancies: a cost-consequence analysis using linked administrative data

Download from doi.org

This paper was not found in any repository; the policy of its publisher is unknown or unclear.

2023 Abdulazeez Salawu, Ben X. Wang, Ming Han, Caryn Geady, Alya Heirali, Hal K. Berman, Thomas D. Pfister, Alberto Hernando-Calvo

, Esmail Mutahar Al-Ezzi, Lee-Anne Stayner, Abha A. Gupta, Olubukola Ayodele, Bernard Lam, Aaron R. Hansen, Anna Spreafico and 7 other authors

Supplementary Figure S1 from Safety, Immunologic, and Clinical Activity of Durvalumab in Combination with Olaparib or Cediranib in Advanced Leiomyosarcoma: Results of the DAPPER Clinical Trial.

Upload

Abdulazeez Salawu, Ben X. Wang, Ming Han, Caryn Geady, Alya Heirali, Hal K. Berman, Thomas D. Pfister, Alberto Hernando-Calvo

, Esmail Mutahar Al-Ezzi, Lee-Anne Stayner, Abha A. Gupta, Olubukola Ayodele, Bernard Lam, Aaron R. Hansen, Anna Spreafico and 7 other authors

Supplementary Table S3 from Safety, Immunologic, and Clinical Activity of Durvalumab in Combination with Olaparib or Cediranib in Advanced Leiomyosarcoma: Results of the DAPPER Clinical Trial.

Upload

Abdulazeez Salawu, Ben X. Wang, Ming Han, Caryn Geady, Alya Heirali, Hal K. Berman, Thomas D. Pfister, Alberto Hernando-Calvo

, Esmail Mutahar Al-Ezzi, Lee-Anne Stayner, Abha A. Gupta, Olubukola Ayodele, Bernard Lam, Aaron R. Hansen, Anna Spreafico and 7 other authors

Supplementary Table S1 from Safety, Immunologic, and Clinical Activity of Durvalumab in Combination with Olaparib or Cediranib in Advanced Leiomyosarcoma: Results of the DAPPER Clinical Trial.

Upload

Abdulazeez Salawu, Ben X. Wang, Ming Han, Caryn Geady, Alya Heirali, Hal K. Berman, Thomas D. Pfister, Alberto Hernando-Calvo

, Esmail Mutahar Al-Ezzi, Lee-Anne Stayner, Abha A. Gupta, Olubukola Ayodele, Bernard Lam, Aaron R. Hansen, Anna Spreafico and 7 other authors

Supplementary Table S2 from Safety, Immunologic, and Clinical Activity of Durvalumab in Combination with Olaparib or Cediranib in Advanced Leiomyosarcoma: Results of the DAPPER Clinical Trial.

Upload

Abdulazeez Salawu, Ben X. Wang, Ming Han, Caryn Geady, Alya Heirali, Hal K. Berman, Thomas D. Pfister, Alberto Hernando-Calvo

, Esmail Mutahar Al-Ezzi, Lee-Anne Stayner, Abha A. Gupta, Olubukola Ayodele, Bernard Lam, Aaron R. Hansen, Anna Spreafico and 7 other authors

Data from Safety, Immunologic, and Clinical Activity of Durvalumab in Combination with Olaparib or Cediranib in Advanced Leiomyosarcoma: Results of the DAPPER Clinical Trial.

Upload

Abdulazeez Salawu, Ben X. Wang, Ming Han, Caryn Geady, Alya Heirali, Hal K. Berman, Thomas D. Pfister, Alberto Hernando-Calvo

, Esmail Mutahar Al-Ezzi, Lee-Anne Stayner, Abha A. Gupta, Olubukola Ayodele, Bernard Lam, Aaron R. Hansen, Anna Spreafico and 7 other authors

Supplementary Methods S1 from Safety, Immunologic, and Clinical Activity of Durvalumab in Combination with Olaparib or Cediranib in Advanced Leiomyosarcoma: Results of the DAPPER Clinical Trial.

Upload

Alberto Hernando‐Calvo

, S. Y. Cindy Yang, Eoghan Malone

, Daphne Day, Amy Prawira, Ilan Weinreb, Horace Wong, Angela Rodriguez, Sarah Jennings, Anneli Eliason, Lisa Wang, Anna Spreafico, Lillian L. Siu, Aaron R. Hansen

Selinexor for the treatment of recurrent or metastatic salivary gland tumors: Results from the GEMS‐001 clinical trial

Download from doi.org

Distributing this paper is prohibited by the publisher

Alberto Hernando-Calvo

, Maria Vila-Casadesús, Yacine Bareche, Alberto Gonzalez-Medina, Farnoosh Abbas-Aghababazadeh, Deborah Lo Giacco, Agatha Martin

, Omar Saavedra, Irene Brana, Maria Vieito

, Roberta Fasani, John Stagg, Francesco Mancuso, Benjamin Haibe-Kains, Ming Han and 27 other authors

A pan-cancer clinical platform to predict immunotherapy outcomes and prioritize immuno-oncology combinations in early-phase trials

Upload

Abdulazeez Salawu

, Ben X. Wang

, Ming Han

, Caryn Geady

, Alya Heirali

, Hal K. Berman

, Thomas D. Pfister

, Alberto Hernando-Calvo

, Esmail Mutahar Al-Ezzi

, Lee-Anne Stayner

, Abha A. Gupta

, Olubukola Ayodele

, Bernard Lam

, Aaron R. Hansen

, Anna Spreafico

and 7 other authors

Safety, Immunologic, and Clinical Activity of Durvalumab in Combination with Olaparib or Cediranib in Advanced Leiomyosarcoma: Results of the DAPPER Clinical Trial.

Upload

Philippe Bedard, Alberto Hernando-Calvo

, Cindy Yang, Maria Vila-Casadesús, Ming Han, Amy Liu, Hal Berman, Anna Spreafico, Albiruni Razak, Stephanie Lheureux, Aaron Hansen, Deborah Lo Giacco, Judit Matito, Trevor Pugh, Scott Bratman and 8 other authors

External validation of the VIGex gene-expression signature as a novel predictive biomarker for immune checkpoint treatment

Upload

Alberto Hernando-Calvo

, Elena Garralda

Patient-Centric Approaches for Phase I Combination Trials Come on Stage

Upload

Alberto Hernando-Calvo

, Oriol Mirallas, David Marmolejo, Omar Saavedra, María Vieito

, Juan David Assaf Pastrana, Susana Aguilar, Coro Bescós, Juan Lorente, Jordi Giralt, Sergi Benavente, Jordi Temprana-Salvador, Margarita Alberola, Rodrigo Dienstmann, Elena Garralda

and 3 other authors

Nutritional status associates with immunotherapy clinical outcomes in recurrent or metastatic head and neck squamous cell carcinoma patients

Upload

2022 Guillermo Villacampa, Alberto Hernando-Calvo

, Roger Berché, Omar Saavedra, David Marmolejo, Oriol Mirallas, Irene Braña, Eva Muñoz-Couselo, Elena Garralda

, Rodrigo Dienstmann

Response to “Analysis of the association between prospectively collected immune-related adverse events and survival in patients with solid tumor treated with immune-checkpoint blockers, taking into account immortal-time bias”

Upload

Alberto Hernando-Calvo

, Abdulazeez Salawu

, Rachel Y. Chen

, Daniel V. Araujo, Marc Oliva

, Zhihui Amy Liu, Lillian L. Siu

A risk stratification model for toxicities in phase 1 immunotherapy trials

Upload

Abdulazeez Salawu

, Alberto Hernando-Calvo

, Rachel Y. Chen

, Daniel V. Araujo

, Marc Oliva

, Zhihui A. Liu, Lillian L. Siu

Impact of pharmacodynamic biomarkers in immuno-oncology phase 1 clinical trials

Upload

2021 Alberto Hernando-Calvo

, David W. Cescon, Philippe L. Bedard

Novel classes of immunotherapy for breast cancer

Download from link.springer.com

2020 A. Hernando-Calvo

, A. García-Alvarez, G. Villacampa

, C. Ortiz, D. Bodet, V. García-Patos, J. A. Recio, R. Dienstmann, E. Muñoz-Couselo

Dynamics of clinical biomarkers as predictors of immunotherapy benefit in metastatic melanoma patients

Download from link.springer.com

Missing publications? Search for publications with a matching author name.

Researcher

Statistics

Refine

All papers authored by Alberto Hernando-Calvo